231 related articles for article (PubMed ID: 21789116)
1. Adjuvant therapy for resected non-small cell lung cancer.
Wozniak AJ; Gadgeel SM
Ther Adv Med Oncol; 2009 Sep; 1(2):109-18. PubMed ID: 21789116
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
Wozniak AJ; Gadgeel SM
Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
4. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Tsuboi M; Ohira T; Saji H; Miyajima K; Kajiwara N; Uchida O; Usuda J; Kato H
Ann Thorac Cardiovasc Surg; 2007 Apr; 13(2):73-7. PubMed ID: 17505412
[TBL] [Abstract][Full Text] [Related]
5. Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review.
Bradbury P; Sivajohanathan D; Chan A; Kulkarni S; Ung Y; Ellis PM
Clin Lung Cancer; 2017 May; 18(3):259-273.e8. PubMed ID: 28162945
[TBL] [Abstract][Full Text] [Related]
6. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni L; Vavalà T; Novello S
Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
Heon S; Johnson BE
J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
[TBL] [Abstract][Full Text] [Related]
9. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
10. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
11. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris MG; Mitsudomi T; Peters S
Transl Lung Cancer Res; 2023 Apr; 12(4):824-836. PubMed ID: 37197636
[TBL] [Abstract][Full Text] [Related]
13. [Current status of postoperative adjuvant chemotherapy for completely resected non-small lung cancer].
Tsuboi M
Nihon Geka Gakkai Zasshi; 2014 May; 115(3):125-9. PubMed ID: 24946518
[TBL] [Abstract][Full Text] [Related]
14. [Recent Status of Postoperative Adjuvant Chemotherapy after Completely Resected Lung Cancer].
Naito M; Tsuboi M
Gan To Kagaku Ryoho; 2016 Feb; 43(2):165-9. PubMed ID: 27067681
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
16. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
Johnson BE; Rabin MS
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
[TBL] [Abstract][Full Text] [Related]
17. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
Wakelee H; Dubey S; Gandara D
Oncologist; 2007 Mar; 12(3):331-7. PubMed ID: 17405898
[TBL] [Abstract][Full Text] [Related]
18. [Lung cancer].
Nakagawa K; Kondo H
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1412-5. PubMed ID: 21918337
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
Suehisa H; Toyooka S
Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
